K882 is an inhibitor of Src kinase.1 It binds to Src (Kd = 315 nM), decreases phosphorylation at the tyrosine in position 416 (Y416), a Src activation site, and increases phosphorylation at Y527, an inactivation site. K882 reduces the proliferation of wild-type NCI H358 non-small cell lung cancer cells and NCI H358 cells expressing a KRASG12C mutation (IC50s = 2.14 and 2.03 µM, respectively). It also inhibits migration and invasion of NCI H358 cells when used at concentrations of 2, 4, and 8 µM, induces cell cycle arrest in the G2/M phase at 1, 4, and 8 µM, and induces apoptosis at 4 and 8 µM. K882 (25, 50, and 100 mg/kg) reduces tumor volume in an NCI H358 mouse xenograft model.WARNING This product is not for human or veterinary use.